| Indicators | Browse All

CAMP4 THERAPEUTICS CORPORATION (CAMP)

Healthcare | Biotechnology | Cambridge, United States | NasdaqGM
4.15 USD +0.01 (0.242%) ⇧ (Aug. 28, 2026, 4 p.m. EDT)
After hours: 4.15

Short-term:★★⯪☆☆Long-term:★★⯪☆☆Dividends:☆☆☆☆☆
Hot Take | Aug. 22, 2026, 1:34 a.m. EDT

The immediate outlook is neutral despite a recent price bounce, as the asset lacks a clear directional edge. While the stock rallied sharply in late August, breaking above key moving averages, the underlying business fundamentals remain severely impaired with negative earnings, negative free cash flow, and a negative book value. The massive gap between the current price and the analyst mean target suggests significant upside potential if clinical trials succeed, but the lack of profitability and the 'very low' confidence in short-term statistical models prevent a bullish short-term rating. For the long term, the company is too new to have established a multi-year price trajectory, rendering historical performance irrelevant for this specific metric; however, the absence of revenue growth history combined with deep losses and a negative balance sheet prevents a strong buy rating based on proven business quality. There is no dividend to provide income, making this a pure speculative play on future drug approvals rather than a value investment.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.081251
AutoETS0.081459
AutoARIMA0.081513
MSTL0.082371

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 20%
H-stat 39.96
Ljung-Box p 0.000
Jarque-Bera p 0.012
Excess Kurtosis -0.11
Attribute Value
Sector Healthcare
Revenue per Share 0.086
Market Cap 260,425,792
Forward P/E -5.22
Website https://www.camp4tx.com

Info Dump

Attribute Value
52 Week Change 1.6538463
Address1 One Kendall Square
Address2 3rd Floor Building 1400 West
All Time High 12.3
All Time Low 1.305
Ask 5.46
Ask Size 2
Average Analyst Rating 1.3 - Strong Buy
Average Daily Volume10 Day 327,670
Average Daily Volume3 Month 253,354
Average Volume 253,354
Average Volume10Days 327,670
Bid 2.94
Bid Size 2
Book Value -0.013
City Cambridge
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 4.15
Current Ratio 4.703
Custom Price Alert Confidence HIGH
Date Short Interest 1,786,665,600
Day High 4.295
Day Low 4.04
Display Name Camp4 Therapeutics
Earnings Timestamp End 1,755,028,800
Earnings Timestamp Start 1,755,028,800
Ebitda -50,561,000
Ebitda Margins 0.0
Enterprise To Ebitda -3.489
Enterprise To Revenue 41.841
Enterprise Value 176,399,776
Eps Current Year -1.03863
Eps Forward -0.79476
Eps Trailing Twelve Months -2.31
Esg Populated 0
Exchange NGM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 4.1254
Fifty Day Average Change 0.024600029
Fifty Day Average Change Percent 0.005963065
Fifty Two Week Change Percent 165.38463
Fifty Two Week High 7.75
Fifty Two Week High Change -3.6
Fifty Two Week High Change Percent -0.4645161
Fifty Two Week Low 1.41
Fifty Two Week Low Change 2.7400002
Fifty Two Week Low Change Percent 1.9432626
Fifty Two Week Range 1.41 - 7.75
Financial Currency USD
First Trade Date Milliseconds 1,728,653,400,000
Float Shares 38,058,561
Forward Eps -0.79476
Forward P E -5.2217026
Free Cashflow -12,828,000
Full Exchange Name NasdaqGM
Full Time Employees 48
Fullday Change 0.0100002
Fullday Change Percent 0.241551
Fullday Price 4.15
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Gross Profits -34,474,000
Has Pre Post Market Data 1
Held Percent Insiders 0.09651
Held Percent Institutions 0.79586
Implied Shares Outstanding 62,753,200
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Market us_market
Market Cap 260,425,792
Market State CLOSED
Max Age 86,400
Message Board Id finmb_569025678
Most Recent Quarter 1,782,777,600
Net Income To Common -107,244,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 259,484,482
Number Of Analyst Opinions 6
Open 4.18
Operating Cashflow -28,591,000
Operating Margins -7.5210795
Payout Ratio 0.0
Phone 617 651 8867
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 4.15
Post Market Time 1,787,959,806
Previous Close 4.14
Price Eps Current Year -3.9956481
Price Hint 4
Price To Book -319.23077
Price To Sales Trailing12 Months 61.770824
Profit Margins 0.0
Quick Ratio 4.525
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.28571
Region US
Regular Market Change 0.0100002
Regular Market Change Percent 0.241551
Regular Market Day High 4.295
Regular Market Day Low 4.03
Regular Market Day Range 4.03 - 4.295
Regular Market Open 4.18
Regular Market Previous Close 4.14
Regular Market Price 4.15
Regular Market Time 1,787,947,201
Regular Market Volume 142,058
Return On Assets -0.45251
Return On Equity -5.45854
Revenue Growth 0.188
Revenue Per Share 0.086
Sand P52 Week Change 0.1966995
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 62,753,200
Shares Percent Shares Out 0.020299999
Shares Short 1,276,571
Shares Short Previous Month Date 1,784,073,600
Shares Short Prior Month 1,442,275
Short Name CAMP4 THERAPEUTICS CORPORATION
Short Percent Of Float 0.0278
Short Ratio 6.25
Source Interval 15
State MA
Symbol CAMP
Target High Price 15.0
Target Low Price 6.5
Target Mean Price 9.91667
Target Median Price 8.5
Total Cash 86,398,000
Total Cash Per Share 1.377
Total Debt 2,372,000
Total Revenue 4,216,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -2.31
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 4.483975
Two Hundred Day Average Change -0.33397484
Two Hundred Day Average Change Percent -0.07448187
Type Disp Equity
Volume 142,058
Website https://www.camp4tx.com
Zip 2,139